Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer.
Rajan A, Abdul Sater H, Rahma O, Agajanian R, Lassoued W, Marté JL, Tsai YT, Donahue RN, Lamping E, Bailey S, Weisman A, Walter-Rodriguez B, Ito R, Vugmeyster Y, Sato M, Machl A, Schlom J, Gulley JL. Rajan A, et al. Among authors: lamping e. J Immunother Cancer. 2024 Mar 13;12(3):e008480. doi: 10.1136/jitc-2023-008480. J Immunother Cancer. 2024. PMID: 38485188 Free PMC article. Clinical Trial.
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.
Strauss J, Heery CR, Schlom J, Madan RA, Cao L, Kang Z, Lamping E, Marté JL, Donahue RN, Grenga I, Cordes L, Christensen O, Mahnke L, Helwig C, Gulley JL. Strauss J, et al. Among authors: lamping e. Clin Cancer Res. 2018 Mar 15;24(6):1287-1295. doi: 10.1158/1078-0432.CCR-17-2653. Epub 2018 Jan 3. Clin Cancer Res. 2018. PMID: 29298798 Free PMC article. Clinical Trial.
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies.
Strauss J, Gatti-Mays ME, Cho BC, Hill A, Salas S, McClay E, Redman JM, Sater HA, Donahue RN, Jochems C, Lamping E, Burmeister A, Marté JL, Cordes LM, Bilusic M, Karzai F, Ojalvo LS, Jehl G, Rolfe PA, Hinrichs CS, Madan RA, Schlom J, Gulley JL. Strauss J, et al. Among authors: lamping e. J Immunother Cancer. 2020 Dec;8(2):e001395. doi: 10.1136/jitc-2020-001395. J Immunother Cancer. 2020. PMID: 33323462 Free PMC article. Clinical Trial.
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Heery CR, O'Sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauckhorst M, Lamping E, Oyelakin I, Marté JL, Lepone LM, Donahue RN, Grenga I, Cuillerot JM, Neuteboom B, Heydebreck AV, Chin K, Schlom J, Gulley JL. Heery CR, et al. Among authors: lamping e. Lancet Oncol. 2017 May;18(5):587-598. doi: 10.1016/S1470-2045(17)30239-5. Epub 2017 Mar 31. Lancet Oncol. 2017. PMID: 28373007 Free PMC article. Clinical Trial.
First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors.
Strauss J, Heery CR, Kim JW, Jochems C, Donahue RN, Montgomery AS, McMahon S, Lamping E, Marté JL, Madan RA, Bilusic M, Silver MR, Bertotti E, Schlom J, Gulley JL. Strauss J, et al. Among authors: lamping e. Clin Cancer Res. 2019 Jan 1;25(1):99-109. doi: 10.1158/1078-0432.CCR-18-1512. Epub 2018 Aug 21. Clin Cancer Res. 2019. PMID: 30131389 Free PMC article. Clinical Trial.
A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules.
Gatti-Mays ME, Strauss J, Donahue RN, Palena C, Del Rivero J, Redman JM, Madan RA, Marté JL, Cordes LM, Lamping E, Orpia A, Burmeister A, Wagner E, Pico Navarro C, Heery CR, Schlom J, Gulley JL. Gatti-Mays ME, et al. Among authors: lamping e. Clin Cancer Res. 2019 Aug 15;25(16):4933-4944. doi: 10.1158/1078-0432.CCR-19-0183. Epub 2019 May 20. Clin Cancer Res. 2019. PMID: 31110074 Free PMC article.
A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors.
Gatti-Mays ME, Tschernia NP, Strauss J, Madan RA, Karzai FH, Bilusic M, Redman J, Sater HA, Floudas CS, Toney NJ, Donahue RN, Jochems C, Marté JL, Francis D, McMahon S, Lamping E, Cordes L, Schlom J, Gulley JL. Gatti-Mays ME, et al. Among authors: lamping e. Oncologist. 2023 Apr 6;28(4):364-e217. doi: 10.1093/oncolo/oyac244. Oncologist. 2023. PMID: 36640137 Free PMC article. Clinical Trial.
Correction: Residues forming the gating regions of asymmetric multidrug transporter Pdr5 also play roles in conformational switching and protein folding.
Alhumaidi M, Nentwig LM, Rahman H, Schmitt L, Rudrow A, Harris A, Dillon C, Restrepo L, Lamping E, Arya N, Ambudkar SV, Choy JS, Golin J. Alhumaidi M, et al. Among authors: lamping e. J Biol Chem. 2023 Apr;299(4):104666. doi: 10.1016/j.jbc.2023.104666. Epub 2023 Apr 10. J Biol Chem. 2023. PMID: 37044027 Free PMC article. No abstract available.
Residues forming the gating regions of asymmetric multidrug transporter Pdr5 also play roles in conformational switching and protein folding.
Alhumaidi M, Nentwig LM, Rahman H, Schmitt L, Rudrow A, Harris A, Dillon C, Restrepo L, Lamping E, Arya N, Ambudkar SV, Choy JS, Golin J. Alhumaidi M, et al. Among authors: lamping e. J Biol Chem. 2022 Dec;298(12):102689. doi: 10.1016/j.jbc.2022.102689. Epub 2022 Nov 10. J Biol Chem. 2022. PMID: 36370844 Free PMC article.
53 results